Table 1 Demographics of included studies
Study, Year | Study design/setting | VKA-treated N | Mean age | VKA experience, % | Geographic region | Interpolation method | Self -management | Duration of therapy, months (Patient-years) | VKA studied |
|---|---|---|---|---|---|---|---|---|---|
Abdelhafiz 2004 [11] | PD/AC clinic | 402 | 72 | 0% | Europe | Linear | N | 19 (637) | W |
Abdelhafiz (<75) 2008 [12] | PD/AC clinic | 203 | 64 | 0% | Europe | Linear | N | 19 (321) | W |
Abdelhafiz (≥75) 2008 [12] | 199 | 80 | 19 (315) | ||||||
Akdeniz 2005 [13] | PD/Community | 208 | 66 | NR | Turkey | - | - | - | W |
Albers 2005 [14] | RCT | 1962 | 72 | 85% | N. America | Linear | N | 20 (3270) | W |
Anderson 2004 [15] | RD/AC clinic | 87 | NR | 100% | N. America | NR | N | 12 (87) | W |
Ansell (Italy) 2007 [16] | RD/AC clinic | 177 | 72 | 100% | Multinational | Linear | N | 12 (177) | W |
Ansell (Spain) 2007 [16] | RD/AC clinic | 218 | 72 | 12 (218) | A | ||||
Ansell (US) 2007 [16] | RD/Community | 686 | 75 | 12 (686) | W | ||||
Ansell (Canada) 2007 [16] | RD/Community | 152 | 74 | 12 (152) | W | ||||
Ansell (France) 2007 [16] | RD/Community | 278 | 73 | 12 (278) | F | ||||
Aronow 1999 [17] | PD/Community | 125 | 83 | NR | N. America | NR | N | 34 (354) | W |
Boulanger 2006 [18] | RD/Community | 6454 | 68 | 65% | N. America | Linear | N | 12 (6454) | W |
Burton (<75) 2006 [19] | RD/Community | 260 | NR | Mixed | Europe | Linear | N | 25 (539) | W |
Burton (>75) 2006 [19] | 341 | 15 (414) | |||||||
Cafolla (Manual) 2011 [20] | RD/Community | 576 | NR | 100% | Europe | Linear | N | 8 (384) | A,W |
Cafolla 2012 [21] | PD/AC clinic | 57 | 85 | 100% | Europe | Linear | N | 18 (86) | W |
Cheung 2005 [22] | RD/Community | 555 | 70 | 100% | Asia | - | N | 19 (893) | W |
Chung 2011 [23] | RCT | 75 | 65 | 55% | Asia | Linear | N | 3 (19) | W |
Connolly 1991 [24] | RCT | 187 | 68 | 0% | N. America | Linear | N | 15 (234) | W |
Connolly 2006 [25] | RCT | 3371 | 70 | 78% | N. America | Other | N | 15 (4214) | NR |
Copland 2001 [26] | RD/AC Clinic | 328 | 70 | 100% | UK | - | N | 21 (458) | W |
Currie (stable) 2005 [27] | RD/Community | 787 | 74 | 100% | Europe | Linear | N | 35 (2282) | W |
Currie (unstable) 2005 [27] | 726 | 78 | 35 (2105) | ||||||
Dentali 2012 [28] | PD/AC Clinic | 221 | 75 | 100 | Europe | - | N | 3 (663) | W |
DiMarco 2005 [29] | RCT | NR | 70 | NR | N. America | - | N | 42 (−) | W |
Dimberg (control SP) 2012 [30] | RD/Community | 84 | 69 | 100% | Europe | Linear | N | 12(84) | W |
Dimberg (control ACC) 2012 [30] | RD/AC clinic | 271 | 72 | 12(271) | |||||
EAFT 1995 [31] | RCT | 214 | 71 | 0% | Europe | - | N | 24 (377) | W,A,F |
Ellis 2009 [32] | RCT | 66 | 68 | 97% | N. America | Linear | N | 3 (17) | T |
Evans 2000 [33] | PD/AC clinic | 288 | 76 | 0% | Europe | NR | N | 24 (576) | W |
Evans 2001 [34] | PD/AC clinic | 214 | 78 | NR | Europe | NR | N | 24 (448) | W |
Ezekowitz 2007 [35] | RCT | 70 | 69 | 100% | Multinational | NR | N | 3 (18) | W |
Fang 2004 [36] | RD/AC Clinic | 170 | 78 | 100 | N. America | - | N | - | W |
Gallagher 2011 [37] | RD/Community | 18113 | 73 | 72% | Europe | Linear | N | 20 (30188) | W |
Garcia (naïve) 2013 [38] | RCT | 3888 | 70 | 0% | Multinational | Linear | N | 22 (7128) | W |
Garcia (exp) 2013 [38] | 5193 | 70 | 100% | 22 (9521) | |||||
Gladstone 2009 [39] | RD/Community | 423 | 78 | 100 | N. America | - | N | - | W |
Go 2003 [40] | RD/AC clinic | 7445 | 71 | Mixed | N. America | Linear | N | 21 (12958) | W |
Gullov 1998 [41] | RCT | 170 | 73 | 0% | Europe | Linear | N | 25 (355) | W |
Gullov 1999 [42] | RCT | 170 | 73 | 0 | Europe | Linear | N | 25 (355) | W |
Gurwitz 1997 [43] | RD/Community | 117 | 83 | 32% | N. America | Linear | N | 12 (117) | W |
Hannon 2011 [44] | PD/Community | 43 | 77 | 100 | Europe | - | N | - | W |
Hart 2011 [45] | RCT | 523 | NR | 0 | N. America | - | N | 13 (575) | W |
Heidinger 2000 [46] | RD/Community | 753 | 62 | 100% | Europe | NR | Y | 12 (769) | NR |
Hellemons 1999 [47] | RCT | 131 | 70 | 0 | Europe | - | N | 32 (354) | P,A |
Ho (hypertension) 2011 [48] | RD/Community | 278 | 70 | NR | Multinational | Linear | N | 48 (1112) | W |
Ho (no HTN) 2011 [48] | 198 | 69 | 48 (792) | ||||||
Holmes 2009 [49] | RCT | 244 | 73 | 100% | Multinational | NR | N | 18 (366) | W |
Hori 2012 [50] | RCT | 250 | 71 | 90% | Asia | Linear | N | 30 (625) | W |
Hylek 2003 [51] | RD/Community | 188 | 76 | 100 | N. America | - | N | - | W |
Hylek 2007 [52] | PD/AC clinic | 472 | 77 | 0% | N. America | Linear | N | 12 (360) | W |
Jacobs 2009 [53] | RD/Community | 90 | NR | 85% | N. America | Linear | N | 12 (90) | W |
Jones 2005 [54] | RD/Community | 2223 | 72 | 100% | Europe | Linear | N | 31 (5743) | W |
Kalra 2000 [55] | PD/AC clinic | 167 | 77 | 0% | Europe | Linear | N | 24 (296) | W |
Kim 2009 [56] | RD/AC clinic | 129 | 64 | 100% | Asia | Other | N | 24 (258) | W |
Kim 2010 [57] | PD/AC clinic | 499 | 73 | 100% | N. America | Linear | N | 5 (208) | W |
Kulo (warfarin) 2009 [58] | PD/Community | 60 | 66 | 100% | Europe | NR | N | 12 (60) | W |
Kulo (acenocoumarol) 2009 [58] | 57 | 68 | 12 (57) | A | |||||
Lee 2012 [59] | RD/Community | 200 | 67 | NR | Asia | Linear | N | 42 (700) | W |
Malik 2000 [60] | RD/AC clinic | 247 | 68 | 100% | N. America | Other | N | 13 (268) | W |
Mant 2007 [61] | RCT | 488 | 82 | 40% | Europe | Linear | N | 32 (1301) | W |
Matchar (control) 2002 [62] | RCT | 317 | 76 | NR | N. America | Linear | N | 9 (238) | W |
Matchar (prior to ACC) 2002 [62] | PD/AC clinic | 363 | 75 | 9 (272) | |||||
McBride 2007 [63] | PD/Community | 361 | 71 | 90% | Europe | Linear | N | 9 (271) | W |
McCormick 2001 [64] | RD/Community | 174 | 87 | 100% | N. America | Linear | N | 12 (174) | W |
Melamed 2011 [65] | RD/Community | 906 | 72 | 100% | Israel | Linear | N | 10 (769) | W |
Menzin 2005 [66] | RD/AC clinic | 600 | 72 | 63% | N. America | Linear | N | 11 (525) | W |
Morocutti 1997 [67] | RCT | 454 | 72 | NR | Europe | - | N | 12 | W |
Neree 2006 [68] | RD/Community | 395 | 74 | 100% | Europe | Linear | N | 4 (132) | P,A,W |
Nichol (ACC) 2008 [69] | RD/AC clinic | 351 | NR | 100% | N. America | Linear | N | 31 (920) | W |
Nichol (UC) 2008 [69] | RD/Community | 756 | 18 (1165) | ||||||
Njaastad 2006 [70] | RD/AC clinic | 421 | NR | 0% | Europe | Linear | N | 14 (475) | W |
Nozawa 2001 [71] | PD/Community | 156 | 68 | 100 | Asia | - | N | 22 (286) | W |
Ogawa 2011 [72] | RCT | 75 | 72 | 0 | Asia | Linear | N | 3 (210) | W |
Okumura (<70) 2011 [73] | PD/Community | 208 | NR | 100% | Asia | Linear | N | 23 (399) | W |
Olsson 2003 [74] | RCT | 1703 | 70 | 73% | Multinational | NR | N | 16 (2271) | W |
Ono 2005 [75] | PD/Community | 63 | 76 | 0 | Asia | Linear | N | 28 (145) | W |
Patel 2011 [76] | RCT | 7133 | 73 | 63% | Multinational | Linear | N | 20 (11888) | W |
Pengo 1998 [77] | RCT | 153 | 74 | 0% | Europe | Linear | N | 14 (179) | W |
Pengo 2001 [78] | PD/AC Clinic | 433 | 68 | 0 | Europe | Linear | N | 17 (615) | W,A |
Pengo 2010 [79] | RCT | 132 | 79 | 0% | Multinational | Linear | N | 64 (704) | W |
Perez-Gomez 2004 [80] | RCT | 237 | 70 | 0% | Europe | NR | N | 33 (556) | A |
Poli 2007 [81] | PD/AC clinic | 290 | 82 | 100% | Europe | Linear | N | 34 (814) | NR |
Poli 2009 [82] | PD/AC Clinic | 783 | 75 | 0% | Europe | Linear | N | 39 (2567) | W |
Poli 2009 [83] | PD/AC clinic | 578 | 75 | 100% | Europe | Linear | N | 38 (1854) | NR |
Poli 2009 [84] | PD/AC clinic | 780 | 75 | 100 | Europe | Linear | N | 36 (2406) | W |
Poller (Manual) 2008 [85] | RCT | 2967 | 67 | 0% | Multinational | Linear | N | 17 (4203) | W, A, P |
Sadanaga 2010 [86] | PD/Community | 259 | 74 | 100 | Asia | - | N | 25 (544) | W |
Samsa (ACC) 2000 [87] | RD/AC Clinic | 43 | 69 | NR | N. America | Linear | N | 9 (32) | W |
Samsa (Rochester) 2000 [87] | RD/Community | 61 | 9 (46) | ||||||
Samsa (R. Triangle) 2000 [87] | RD/Community | 125 | 9 (94) | ||||||
Schwammenthal 2010 [88] | PD/Community | 111 | 76 | 100 | Israel | - | N | - | W |
Sconce (vitamin K) 2007 [89] | RCT | 35 | 75 | 100% | Europe | Linear | N | 6 (18) | W |
Sconce (placebo) 2007 [89] | 35 | 74 | |||||||
Shen 2007 [90] | RD/Community | NR | 72 | 55% | N. America | NR | N | 40 (24179) | W |
Singer 2009 [91] | RD/Community | 9217 | 77 | 100 | N. America | - | N | 72 (33497) | W |
SPAF III 1996 [92] | RCT | 523 | 71 | 56% | N. America | NR | N | 13 (567) | W |
Sullivan (women) 2012 [93] | RCT | 1594 | 71 | 87% | Multinational | Linear | N | 42 (5579) | W |
Sullivan (men) 2012 [93] | 2466 | 68 | 86% | 42 (8631) | |||||
Tincani 2009 [94] | PD/AC Clinic | 90 | 92 | 100% | Europe | Linear | N | 12 (90) | W |
Van Spall 2012 [95] | RCT | 6022 | 72 | 47% | Multinational | Linear | N | 24 (12044) | W |
Voller (self-mgmt) 2005 [96] | RCT | 101 | 65 | 0% | Europe | NR | Y | 8 (68) | NR |
Voller (UC) 2005 [96] | 101 | 64 | N | ||||||
Walker (MHC) 2011 [97] | RD/AC Clinic | 22 | NR | 100% | N. America | Linear | N | 12 (22) | W |
Walker (no MHC) 2011 [97] | 62 | 12 (62) | |||||||
Wieloch (AF) 2011 [98] | RD/Community | 11770 | 73 | 100% | Europe | Linear | N | 12 (11770) | W |
Weitz 2010 [99] | RCT | 250 | 66 | 35% | N. America | Linear | N | 3 (63) | W |
Wyse 2002 [100] | RCT | NR | 70 | NR | N. America | - | N | 42 | W |
Yamaguchi 2000 [101] | RCT | 55 | 66 | NR | Asia | - | N | 22 (101) | W |
Yasaka 2001 [102] | PD/Community | 88 | 100 | Asia | - | N | 22 (161) | W | |
Yousef 2004 [103] | RD/Community | 739 | 73 | 100% | Europe | NR | N | 24 (1484) | W |